Interested to learn more about MVA based vaccines and their uses and advantages? Continue reading to see what Stephen Lockhart, Senior Vice President, Product Development, Emergent Biosolutions, UK has to say.
Stephen Lockhart heads the Product Development Division within Emergent Biosolutions. Emergent Biosolutions develops, manufactures and commercialises vaccines and immune-based therapeutics for infectious diseases, oncology and autoimmune diseases. It produces BioThraxÂ® (Anthrax Vaccine Adsorbed), the only FDA licensed vaccine for anthrax. Vaccines in clinical development include MVA85A for prevention of TB, an oral typhoid candidate vaccine for prevention of typhoid and a recombinant anthrax candidate vaccine.
Here are some of the issues that Stephen Lockhart discussed, at the World Influenza Congress Asia Summit 2011:
1. What is MVA based vaccine?
2. Uncovering new MVA based candidate vaccines
3. Exploring new MVA based candidate vaccines for infectious diseases in Asia such as tubercolosis and avian influenza
Click here to download and view his slides now!